Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists

• Published in: Child's nervous system Vol. 32; no. 1; pp. 61 - 64
• Main Authors: Jaeger, Mariane, Ghisleni, Eduarda C., Fratini, Lívia, Brunetto, Algemir L., Gregianin, Lauro José, Brunetto, André T., Schwartsmann, Gilberto, de Farias, Caroline B., Roesler, Rafael
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2016
• Subjects: Analysis of Variance; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Bombesin - analogs & derivatives; Bombesin - pharmacology; Brief Communication; Cell Line, Tumor; Cell Survival - drug effects; Dose-Response Relationship, Drug; Histone Deacetylase Inhibitors - pharmacology; Humans; Medicine; Medicine & Public Health; Medulloblastoma - pathology; Neurosciences; Neurosurgery; Peptide Fragments - pharmacology; Peptides, Cyclic - pharmacology; Receptors, Bombesin - antagonists & inhibitors; Brain tumor; Neuromedin B receptor; Sodium butyrate; Gastrin-releasing peptide receptor

Purpose Medulloblastoma (MB) comprises four distinct molecular subgroups, and survival remains particularly poor in patients with Group 3 tumors. Mutations and copy number variations result in altered epigenetic regulation of gene expression in Group 3 MB. Histone deacetylase inhibitors (HDACi) redu...